

OCT 03 2001
TECH CENTER 1600/2900

Page 1 of 12

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1669.0040001/SRL

APPLICATION NO.
09/817,229

APPLICANT
Ferguson et al.

FILING DATE
March 27, 2001

GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
OC	AA1	4,537,885	08/27/1985	Wattthey	514	183	02/09/1984
	AB1	5,532,245	07/02/1996	Butera et al.	514	272	06/07/1995
not present	AC1	5,565,483	10/15/1996	Hewawasam et al.	514	411	06/07/1995
	AD1	5,602,169	02/11/1997	Hewawasam et al.	514	418	04/19/1996
	AE1	5,605,909	02/25/1997	Butera et al.	514	307	02/14/1996
	AF1	5,750,574	05/12/1998	Gilbert	514	604	07/07/1997
	AG1	5,837,702	11/17/1998	Rovnyak et al.	514	218	08/30/1994
OC	AH1	5,869,478	02/09/1999	Ding et al.	514	212	06/07/1995
	AI1	5,869,509	02/09/1999	Romine et al.	514	364	07/30/1997
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL1	CA 2,132,766	04/08/1995	Canada			Yes No
	AM1	CA 2,202,578	10/15/1997	Canada			Yes No
OC	AN1	WO 97/49692	12/31/1997	WIPO			Yes No
	AO1	WO 98/16185	04/23/1998	WIPO			Yes No
	AP1	WO 99/07832	02/18/1999	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

OC	AR	1	"Effects of Hypertension," in <i>Harrison's Principles of Internal Medicine</i> , 14th Edition, Harrison, T.R. and Fauci, A., eds., McGraw-Hill, Inc., New York, NY, pp. 1384-1393 (1997).
OC	AS	1	Ahmad, S., "Angiotensin receptor antagonists delay nitric oxide-deficient stroke in stroke-prone rats," <i>Eur. J. Pharmacol.</i> 333:39-45, Elsevier Science B.V. (1997).
OC	AT	1	An, W.F. et al., "Modulation of A-type potassium channels by a family of calcium sensors," <i>Nature</i> 403:553-556, MacMillan Publishing Group (February 2000).


EXAMINER

Chunfeng Wang

DATE CONSIDERED

03/08/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED
OCT 03 2001
TECH CENTER 1600/2900

Page 2 of 12

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1669.0040001/SRL

APPLICATION NO.
09/817,229

APPLICANT
Ferguson et al.

FILING DATE
March 27, 2001

GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


<i>document not present</i>	AR	2	Bains, J.S. and Ferguson, A.V., "Reduced NMDA receptor sensitivity may underlie the resistance of subpopulations of PVN neurons to excitotoxicity," <i>NeuroReport</i> 8:2101-2105, Rapid Science Publishers (1997).
<i>OC</i>	AS	2	Bains, J.S. and Ferguson, A.V., "Hyperpolarizing after-potentials regulate generation of long-duration plateau depolarizations in rat paraventricular nucleus neurons," <i>Eur. J. Neurosci.</i> 10:1412-1421, European Neuroscience Association (1998).
<i>OC</i>	AT	2	Brooks, D.P. et al., "Pharmacology of eprosartan, an angiotensin II receptor antagonist: Exploring hypotheses from clinical data," <i>Am. Heart J.</i> 138:S246-S251, Mosby, Inc. (September 1999).

EXAMINER

Chen/Smith

DATE CONSIDERED *03/08/02*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



OCT 03 2001
TECH CENTER 1600/2900

Page 3 of 12

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1669.0040001/SRL

APPLICATION NO.
09/817,229

APPLICANT
Ferguson et al.

FILING DATE
March 27, 2001

GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

OC	AR	3	Brunner, H.R. et al., "Chapter 86: Angiotensin Antagonists," in <i>The Renin-Angiotensin System, Vol. 2: Biochemistry, Physiology, Pathophysiology and Therapeutics</i> , Robertson, J.I.S. and Nicholls, M.G., eds., Gower Medical Publishing, London, England, Figs. 86.5-86.11, pp. 86.1, 86.4, 86.5, 86.16 (1993).
OC	AS	3	Burrell, L.M. et al., "Long-term effects of nonpeptide vasopressin V ₂ antagonist OPC-31260 in heart failure in the rat," <i>Am. J. Physiol.</i> 275:H176-H182, American Physiological Society (1998).
OC	AT	3	Chen, Y.L. et al., "Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V _{1A} receptors," <i>Eur. J. Pharmacol.</i> 376:45-51, Elsevier Science, Inc. (July 1999).

EXAMINER

William B. Smith

DATE CONSIDERED

03/02/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OCT 03 2001

TECH CENTER 1600/2900

Page 4 of 12



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1669.0040001/SRLAPPLICATION NO.
09/817,229APPLICANT
Ferguson et al.FILING DATE
March 27, 2001GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

OC	AR	4	Dai, W.-J. et al., "Blockade of Central Angiotensin AT ₁ Receptors Improves Neurological Outcome and Reduces Expression of AP-1 Transcription Factors After Focal Brain Ischemia in Rats," <i>Stroke</i> 30:2391-2399, editorial comment, pp. 2398-2399, American Heart Association, Inc. (November 1999).
OC	AS	4	Easton, J.D. et al., "Chapter 366: Cerebrovascular Diseases," in <i>Harrison's Principles of Internal Medicine, 14th Edition</i> , Harrison, T.R. and Fauci, A., eds., McGraw-Hill, Inc., New York, NY, pp. 2325-2339 (1997).
OC	AT	4	Fournier, A. et al., "Could Angiotensin II Type I Receptor Antagonists (aratl) Better Prevent Stroke than Angiotensin II Converting Enzyme Inhibitors (ACE I)?" <i>Arch. Mal. Coeur Vaiss.</i> 92:997-1000, Editions J.B. Bailliere (August 1999).

EXAMINER

DATE CONSIDERED

03/08/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



OCT 03 2001

TECH CENTER 1600/2900

Page 5 of 12

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1669.0040001/SRLAPPLICATION NO.
09/817,229APPLICANT
Ferguson et al.FILING DATE
March 27, 2001GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

OC	AR	<u>5</u>	Fujita, H. et al., "The Effect of Vasopressin V1- and V2-Receptor Antagonists on Hemodynamics in Early and Late Phase After Myocardial Infarction in Rats," <i>Jpn. J. Pharmacol.</i> 78:229-232, Japanese Pharmacological Society (1998).
OC	AS	<u>5</u>	Gehlert, D.R. et al., "Non-peptide angiotensin II receptor antagonists discriminate subtypes of ¹²⁵ I-angiotensin II binding sites in the rat brain," <i>Eur. J. Pharmacol.</i> 187:123-126, Elsevier Science Publishers B.V. (Biomedical Division) (1990).
OC	AT	<u>5</u>	Gehlert, D.R. et al., "Autoradiographic Localization of Subtypes of Angiotensin II Antagonist Binding in the Rat Brain," <i>Neuroscience</i> 44:501-514, Pergamon Press plc (1991).

EXAMINER

DATE CONSIDERED 03/01/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED
OCT 03 2001
TECH CENTER 1600/2900

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1669.0040001/SRL	APPLICATION NO. 09/817,229
APPLICANT Ferguson et al.	
FILING DATE March 27, 2001	GROUP 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

oc	AR	6	Inada, Y. et al., "Protective Effects of Candesaratan Cilexetil (TCV-116) Against Stroke, Kidney Dysfunction and Cardiac Hypertrophy in Stroke-Prone Spontaneously Hypertensive Rats," Clin. Exp. Hypertens. 19:1079-1099, Marcel Dekker Inc. (1997).
oc	AS	6	Kirk, J.K., "Angiotensin-II Receptor Antagonists: Their Place in Therapy," Amer. Fam. Physician 59:3140-3148, American Academy of Family Physicians (June 1999).
oc	AT	6	Kostrzewska, A. et al., "Effects of the vasopressin V _{1a} receptor antagonist, SR 49059, on the response of human uterine arteries to vasopressin and other vasoactive substances," Acta Obstet. Gynecol. Scand. 77:3-7, Munksgaard International Publishers Ltd. (1998).

EXAMINER <i>Cheng</i>	DATE CONSIDERED 03/08/02
--------------------------	-----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

OCT 03 2001

TECH CENTER 1600/2900

Page 7 of 12

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1669.0040001/SRLAPPLICATION NO.
09/817,229APPLICANT
Ferguson et al.FILING DATE
March 27, 2001GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

ac	AR	7	Li, H. et al., "Caspase Inhibitors Reduce Neuronal Injury After Focal but Not Global Cerebral Ischemia in Rats," <i>Stroke</i> 31:176-182, Lippincott Williams & Wilkins and The American Heart Association (January 2000).
oc	AS	7	Li, Z. et al., "Functional Evidence That the Angiotensin Antagonist Losartan Crosses the Blood-Brain Barrier in the Rat," <i>Brain Res. Bull.</i> 30:33-39, Pergamon Press Ltd. (1993).
oc	AT	7	Li, Z. and Ferguson, A.V., "Electrophysiological Properties of Paraventricular Magnocellular Neurons in Rat Brain Slices: Modulation of I _A by Angiotensin II," <i>Neuroscience</i> 71:133-145, Elsevier Science Ltd. (1996).

EXAMINER

DATE CONSIDERED

03/08/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

OCT 03 2001

TECH CENTER 1600/2900
Page 8 of 12

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1669.0040001/SRLAPPLICATION NO.
09/817,229APPLICANT
Ferguson et al.FILING DATE
March 27, 2001GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

OC	AR	8	Matsuhisa, A. et al., "Nonpeptide Arginine Vasopressin Antagonists for Both V _{1A} and V ₂ Receptors: Synthesis and Pharmacological Properties of 4'-(1,4,5,6-Tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanilide Derivatives and 4'-(5,6-Dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilide Derivatives," <i>Chem. Pharm. Bull. (Tokyo)</i> 48:21-31, Pharmaceutical Society of Japan (January 2000).
OC	AS	8	Nakamura, Y. et al., "Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V _{1A} receptor," <i>Eur. J. Pharmacol.</i> 391:39-48, Elsevier Science B.V. (March 2000).
OC	AT	8	Naito, A. et al., "Pharmacological Profile of VP-343, a Novel Selective Vasopressin V ₂ Receptor Antagonist, in Rats," <i>Biol. Pharm. Bull.</i> 23:182-189, The Pharmaceutical Society of Japan (February 2000).

EXAMINER

DATE CONSIDERED 03/08/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

OCT 03 2001

TECH CENTER 1600/2900
Page 9 of 12

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1669.0040001/SRLAPPLICATION NO.
09/817,229APPLICANT
Ferguson et al.FILING DATE
March 27, 2001GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


OC	AR	9	Nishimura, M. et al., "Cerebral adenosine triphosphate-sensitive K ⁺ channels may be impaired during acute cerebral ischemia in spontaneously hypertensive rats," J. Auton. Nerv. Syst. 58:139-146, Elsevier Science B.V. (1996).
OC	AS	9	Ravati, A. et al., "Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats," Eur. J. Pharmacol. 373:21-33, Elsevier Science B.V. (May 1999).
OC	AT	9	Rogawski, M.A., "The A-current: how ubiquitous a feature of excitable cells is it?" TINS 8:214-219, Elsevier Science Publishers B.V. (1985).

EXAMINER

Chunfeng

DATE CONSIDERED 03/12/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

OCT 03 2001

TECH CENTER 1600/2900
Page 10 of 12

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1669.0040001/SRLAPPLICATION NO.
09/817,229APPLICANT
Ferguson et al.FILING DATE
March 27, 2001GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

OC	AR	10	Serradeil-Le Gal, C., "Effects of SR 49059, a non-peptide antagonist of vasopressin V _{1a} receptors, on vasopressin-induced coronary vasoconstriction in conscious rabbits," <i>Fundam. Clin. Pharmacol.</i> 9:17-24, Elsevier, Paris (1995).
OC	AS	10	Stier Jr., C.T. et al., "Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats," <i>J. Hypertens.</i> 11:S37-S42, Current Science Ltd. (1993).
OC	AT	10	Storm, J.F., "Temporal integration by a slowly inactivating K ⁺ current in hippocampal neurons," <i>Nature</i> 336:379-381, Macmillan Publishing Group (1988).


EXAMINER

Chunfeng Shun

DATE CONSIDERED

03/08/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

OCT 03 2001

TECH CENTER 1600/2900
Page 11 of 12

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1669.0040001/SRLAPPLICATION NO.
09/817,229APPLICANT
Ferguson et al.FILING DATE
March 27, 2001GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

OC	AR	11	Takagi, N. et al., "The Effect of Transient Global Ischemia on the Interaction of Src and Fyn with the N-methyl-D-Aspartate Receptor and Postsynaptic Densities: Possible Involvement of Src Homology 2 Domains," J. Cereb. Blood Flow Metab. 19:880-888, Lippincott Williams & Wilkins, Inc. (August 1999).
OC	AS	11	Tanaka, T. et al., "Facilitatory effect of vasopressin on the ischemic decrease of the CA1 presynaptic fiber spikes in rat hippocampal slices," Brain Res. 644:343-346, Elsevier Science B.V. (1994).
OC	AT	11	von Lutterotti, N. et al., "Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats," J. Hypertension 10:949-957, Current Science Ltd. (1992).

EXAMINER

Chung

DATE CONSIDERED

03/08/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

OCT 03 2001

TECH CENTER 1600/2900

Page 12 of 12



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1669.0040001/SRLAPPLICATION NO.
09/817,229APPLICANT
Ferguson et al.FILING DATE
March 27, 2001GROUP
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

0c	AR	12	Washburn, D.L.S. et al., "Inhibition of Subfornical Organ Neuronal Potassium Channels by Vasopressin," <i>Neuroscience</i> 93:349-359, Elsevier Science Ltd. (June 1999).
0c	AS	12	Wilson, J.D., "Approach to the Patient with Endocrine and Metabolic Disorders," in <i>Harrison's Principles of Internal Medicine</i> , 14th Edition, Harrison, T.R. and Fauci, A., eds., McGraw-Hill, Inc., New York, NY, pp. 1965, 2038-2039 (1997).
	AT		

EXAMINER

DATE CONSIDERED

03/08/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.